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ABSTRACT
Background: There is an increasing prevalence of asthma and chronic obstructive pulmonary disease
(COPD) worldwide, leading to increased inhaler use. However, there are concerns with inhaler com-
pliance resulting in different patented inhalers and longer-acting formulations. As a result, inhalers are
now among the highest expenditure items in ambulatory care in Scotland leading to multiple initiatives
to keep within budget without compromising care.
Method: This study assesses inhaler utilization and expenditure between 2001 and 2017 alongside
health authority initiatives.
Results: There was an increase by 137% in inhaler utilization between 2001 and 2017, and a two-fold
increase in expenditure, driven by the increasing use of patented combination inhalers to address
concerns. This is very different to the oral markets where expenditure on proton pump inhibitors, statins,
and antihypertensives have fallen considerably recently despite increased volumes due to the increasing
use of low-cost generics. However, inhaler expenditure has started to fall with an increasing use of lower
cost combinations and initiatives to reduce the steroid burden alongside monitoring patient care.
Conclusion: Challenges with using and changing inhalers has meant this market has not followed other
high-volume drug classes following patent loss. This is starting to change, with the situation monitored
to enhance efficient prescribing alongside continued good quality care.
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1. Introduction
There is an increasing prevalence of asthma and chronic
obstructive pulmonary diseases (COPD) worldwide, with
asthma now one of the most common non-communicable
chronic diseases [1]. Globally asthma affects 334 million peo-
ple and is rising particularly in developing countries [1,2],
which negatively impacts on their quality of life and survival
[1]. In the UK, 5.4 million people are currently receiving treat-
ment for asthma, and in Scotland, one in 14 of the population
currently receives treatment for asthma. However, prevalence
rates have plateaued in recent years [3]. Globally, it is esti-
mated there were 251 million cases of COPD in 2016, with the
number of cases likely to rise with increasing aging popula-
tions and more people smoking [4,5]. By 2030, COPD will be
one of the top ten causes of death worldwide without
improvements in prevention and management [2,6,7]. It is
estimated that approximately 3 million people in the UK cur-
rently have COPD [8], with prevalence rates increased by 9%
between 2008 and 2012 [5].
Concerns with the extent of asthma and COPD among
countries, with their associated impact on morbidity and mor-
tality, have resulted in efforts globally, regionally, and nation-
ally to improve patient care, which include guideline
production and quality improvement strategies [1,9–13]. In
the UK, the Quality and Outcomes Framework (QoF) includes
targets to measure, monitor and improve the identification
and management of patients with asthma and COPD [14,15].
In Scotland, there has also been the Scottish Intercollegiate
Guidelines Network (SIGN) guidelines for asthma [16] as well
as the publication of the Clinical Standards guidance for
patients with COPD, recognizing that during the last decade
COPD was the only major cause of death increasing in
Scotland [17]. There was a further update on best practice
guidance for COPD in 2017, with COPD accounting for
122,000 emergency bed days annually in Scotland with an
average inpatient stay costing GB£3000 per patient [8].
There have also been national respiratory prescribing strategies
in Scotland to promote appropriate, evidence-based, and cost-
effective prescribing of treatments for asthma and COPD,
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predominantly inhalers, as NHS Scotland currently spends over GB
£125 million per year on respiratory medicines [18]. Typically, in
patients with asthma, inhaled corticosteroids (ICS) are first-line
treatment followed by combined long-acting β-agonists
(LABAs)/ICS for more severe asthma, with short acting β-agonists
(SABAs) used as rescue ‘reliever’ therapy [1,13,16,19]. Tiotropium is
also nowbeing prescribed for patients with asthma. In COPD, both
LABAs and long-actingmuscarinic antagonists (LAMAs) have been
used alone or in combination, with LAMA use growing with
studies showing a greater effect in reducing exacerbations and
hospitalizations [20,21]. The use of LABA/ICS inhalers for COPD has
also grown in recent years following a number of studies [22–27].
However, there are now concernswith the increased risk of serious
pneumonia [27]. As a result, more recent guidance suggests that
combination LABA/ICS should only principally be prescribed in
COPD patients with asthma-like symptoms with exacerbations in
view of potential adverse effects [12,21]. It can be difficult though
to assess differences in outcomes between the different combina-
tion formulations and inhaler types [28–32]; consequently, the
choice of inhaler device and ease of use do play an appreciable
role in the choice of device prescribedwith poor inhaler technique
known to compromise care [33–37].
Scrutiny regarding the quality and costs of prescribing for
patients with respiratory diseases has grown in recent years
with, as mentioned, NHS Scotland currently spending over GB
£125 million per year on respiratory medicines [18]. This
makes the inhalers the second highest medicine category in
Scotland [18]. Increasing expenditure on inhalers has been
driven by the availability of new patented devices to address
concerns with their effectiveness and adherence despite the
patents on many of the active ingredients expiring, with poor
inhaler technique and adherence known to considerably
increase the costs of asthma and COPD [38]. Concerns with
the overall cost of inhalers in Scotland, but mindful of the
need to ensure good quality care, have also resulted in
a number of initiatives to improve the prescribing of inhalers
to patients with asthma and COPD to help ensure the optimal
use of available resources [19,20,39–41]. This is because both
asthma and COPD can be lifelong conditions once diagnosed,
requiring regular monitoring and review of current therapeu-
tic strategies, presenting a considerable challenge in terms of
the budget implications with different treatment approaches
whilst remaining firmly focused on improving clinical out-
comes along with patient safety. This patient focus has
meant that inhalers are typically prescribed by their brand
name with the potential exception of ABA MDIs. This is
because pharmacists in Scotland are not allowed to substitute
a branded product with a generic [42].
It is envisaged that the inhaler market will be very
different from the typical oral markets where considerable
savings can be made following generic availability as seen
with the Proton Pump Inhibitors (PPIs), statins, and antihy-
pertensives [42–44]. Firstly, there are known concerns with
how well or not patients have used their inhalers in the
past resulting in activities including patient education and
actively involving patients with inhaler choices to help
address this [33,45–50]. As mentioned, concerns with
adherence and poor technique have also resulted in new
inhaler devices being developed as well as new medicines
being developed including LABAs and LAMAs as well as
longer acting steroids. Secondly, there are concerns for
subsequent patient care if patients are switched between
inhaler types without their consent, knowledge or training
[49,51,52]. Lastly, there are concerns with switching
between different inhalers with the same active ingredients
in view of potential issues such as appropriate dosing and
adherence [41].
We are also aware that alternatives to Seretide® and
Symbicort® are typically priced at a discount of only 20% to
30% below originator prices rather than the 85% to 95% reduc-
tions seen for generic PPIs, statins and selective serotonin re-
uptake inhibitors (SSRIs) versus pre-patent loss prices [42,53,54].
As a result, expenditure on LABA/ICS and LAMA inhalers has
grown in recent years to become the highest of any medicine
type in Scotland. To help address this, new lower cost LABA/ICS
inhalers, e.g. Fostair® (beclomethasone/formoterol) and Revlar®
(fluticasone furoate/vilanterol) have recently been promoted by
the Health Boards in Scotland as the preferred first and second
line choices [39–41]. There were concerns initially that these
new inhalers did not have the same dose range as Seretide®
and Symbicort®, which made it difficult to titrate care. In addi-
tion at the time of their launch, there were ongoing initiatives
with Health Boards to encourage physicians to step down
inhaler doses particularly the steroid burden in line with current
guidance (BTS/SIGN). Consequently, it was perceived as challen-
ging to initiate this steroid dose change as well as switch
patients between different inhaler types. There was also
a need for all key stakeholders to become comfortable with
Fostair® or Revlar®, which resulted in a gradual uptake initially
as well as acknowledging the resource implications with patient
training [50]. There have also been concerns with the licensed
indications of these alternatives versus Seretide® and
Symbicort® when initially available.
Consequently, there is a need to investigate the effects of
these multiple national and regional activities on the utilization
and expenditure patterns of the different inhalers used in the
management of asthma and COPD in Scotland. The findings will
be used as a basis for reviewing and debating potential future
policies to improve the quality and efficiency of prescribing for
both asthma and COPD given concerns with expenditure within
resource constrained environments but mindful of the need to
continue to ensure good quality care. We are aware that there
have been publications assessing the impact and factors asso-
ciated with poor inhalation techniques as well as different edu-
cational policies to address concerns [34,37,38,49,50]. However,
we are not aware of any study that has assessed the influence of
multiple international, national and regional policies on inhaler
utilization and expenditure patterns during the past seventeen
years to provide future guidance.
2. Methodology
Utilization and prescribing patterns of inhalers in Scotland were
assessed using the prescription costs analysis (PCA) data com-
piled by the Information Services Division (ISD) of NHS Scotland
from 2001 to 2017 [55]. This is an open source data set collecting
data on the utilization and expenditure of medicines dispensed
in community pharmacies in Scotland. NHS Scotland is
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a universal healthcare system serving the entire Scottish popula-
tion, with currently no co-payment for medicines in Scotland.
The information from the PCA included: the generic (INN) name,
commercial name(s), formulation(s), drug strength(s), number of
dispensed units, cost per unit and total gross expenditure. All
costs are depicted in Great Britain pounds (GB£s). No attempt
was made to allow for inflation as typically medicine costs in
Scotland appreciably fall once generics become available and
prices for originators are typically fixed [42,43].
Data on inhaled medicines from the following classes as
defined by the British National Formulary [56] were incorpo-
rated into the study: SABAs, SAMAs (short acting muscarinic
antagonists), LABAs, LAMAs, mast cell stabilisers, ICS as well as
combinations such as SABA/SAMA, LAMA/LABA, ICS/LABA and
ICS/SABA. We concentrated on guideline-recommended inha-
lers for patients with asthma and COPD, acknowledging that
in patients with asthma a LABA is typically not prescribed
without an ICS and in COPD, an ICS is not licensed without
a LABA. Consequently, both are typically given in combination.
Between 2001 and 2017, 144 individual inhalers were
included covering both originators, alternatives to originators
and generics. In terms of active ingredients, the following were
available during the study period although a number of these
inhaler types are no longer available: five SABAs (salbutamol,
terbutaline sulphate, fenoterol hydrobromide, orciprenaline sul-
phate and reproterol hydrochloride), two SAMAs (ipratropium
bromide and oxitropium bromide), three LABAs (salmeterol, for-
moterol fumarate and olodaterol), three LAMAs (tiotropium, acli-
dinium bromide and umeclidinium bromide), two mast cell
stabilisers (nedocromil sodium and sodium cromoglicate), five
ICS (budesonide, beclometasone dipropionate, ciclesonide, fluti-
casone propionate and mometasone furoate), one SABA/SAMA
(salbutamol with ipratropium), three LAMA/LABA (umeclidinium
bromide with vilanterol trifenatate, aclidinium bromide with for-
moterol fumarate and tiotropium with olodaterol), five ICS/LABA
(salmeterol with fluticasone propionate, budesonide with formo-
terol fumarate, fluticasone furoate with vilanterol, fluticasone
propionate with formoterol fumarate and beclometasone dipro-
pionate with formoterol fumarate) and one ICS SABA (beclome-
tasone dipropionate with salbutamol).
From the PCA data, the units dispensed (typically an inha-
ler) and associated expenditure patterns were calculated for
each drug class. When presenting and assessing utilization
data, NHS Scotland regularly uses defined daily doses (DDDs)
as well as DIDs (DDDs/1000 inhabitants/day) in line with
international guidelines [57–59]. However, for the purpose
of this study, items dispensed in community pharmacies,
which were typically an inhaler, were used in order to track
actual prescriptions to assess the influence of guidelines/
legislation, e.g. encouraging the prescription of combined
LABA/ICS inhalers. In addition, DDDs are not available for
combination inhalers [58]. We used a segmented regression
analysis to assess the influence of the various initiatives to
enhance the prescribing of newer formulations of ICS/LABAs
such as Fostair® or Revlar® as they became increasingly
endorsed by the Health Boards. We also plotted changes in
the utilization and expenditure patterns for the various inha-
ler ingredients over time.
These multiple initiatives undertaken by Scottish Health
Boards and NHS Scotland to influence physician prescribing
were consolidated using the 4E methodology in line with
previous studies: Education (guidelines and academic detail-
ing interventions), Engineering (organizational/managerial
interventions, e.g. prescribing indicators), Economics (financial
incentives for prescribing) and Enforcement (enforced regula-
tions by health authorities – although not generally applying
to Scotland) [42–44,60–63]. Examples of enforcement includ-
ing compulsory INN prescribing in Lithuania, compulsory gen-
eric substitution in Sweden and restrictions on the prescribing
of patented statins in Austria and Finland [64–67]. However,
such activities are difficult in Scotland [42].
No ethical approval was needed as only publicly sourced
aggregated drug utilization, and expenditure data was used
for analysis. No patient level data were accessed.
3. Results
Table 1A in the Appendix summarises the various drug classes,
the name of the first in class, as well as the number of
strengths and formulations available during the course of
the study.
3.1. Demand-side initiatives
Table 1 summarises some of the many NHS Scotland and
Health Board activities during the study period to influence
the utilization and expenditure of inhalers for asthma and
COPD in Scotland. This includes safety concerns if patients
are inappropriately prescribed high dose inhaled steroids as
well as concerns with the increasing costs of Seretide®
[8,16,17,39,40,57,59,68–79].
3.2. Utilization and expenditure patterns
Both utilization and expenditure on inhalers steadily increased
between 2001 and 2017. Total items dispensed increased from
3.45 million units in 2001 to 4.72 million units in 2017 with
expenditure increasing from GB£48.64 million in 2001 to
GB£95.17 million in 2017, respectively (Figures 1 and 2). This
represents a 137.1% increase in items dispensed and 195.7%
increase in total expenditure during the study period.
More specifically, there was a steady increase in dispensed
items for LABAs/ICS during the study period, with the use of
SABAs continually increasing each year as well but at a lower
rate (Figure 1). Alongside this, there was a steady decline in the
use of single-agent ICS inhalers and single-agent LABA inhalers,
reflecting recommended treatment approaches (Table 1). There
has also been an increase in the prescribing of LAMAs following
their availability and more recently LAMA/LABA combinations
but from a low base. Conversely, a steady decline in the use of
SABAs and SAMAs in combination (Figure 1) and limited use
throughout of ICS/SABA combinations. The decline in the use of
ICS/SABA combinations reflects their withdrawal from the mar-
ket place.
During this period, there was also a steady increase in expen-
diture on combination LABA/ICS until recently (Figure 2), as well as
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increased expenditure on LAMAs. Expenditure on these
combination inhalers and LAMAs has driven the increase in expen-
diture on inhalers in Scotland in recent years. Overall, expenditure
on these combination inhalers and LAMAs rose from 8.6% of total
inhaler expenditure in 2001, to 32.4% in 2004, to 62.8% in 2009
soon after the launch of LAMAs, and 75.4% in 2017.
There has been a steady decline in the utilization and
expenditure of originator LABAs/ICS in recent years following
the availability and endorsement of alternative inhalers, e.g.
Fostair® and Relvar® (Table 1) (Figures 3 and 4). It is envisaged
that the utilization of LABA/ICS combinations will plateau or
even fall following the change in GOLD guidance (Table 1).
The change in the prescribing of Seretide® and Symbicort® to
alternative inhalers such as Fostair® and Relvar® has been
significant, i.e. p < 0.001.
As seen (Figure 4), this change in LABA/ICS utilization
patterns (Figure 3) has resulted in their expenditure falling in
recent years with growing use of lower priced alternative
inhalers (Fostair® and Relvar®). In addition, initiatives to encou-
rage lower strength steroid inhalers in recent years (Table 1)
also facilitated in reduced expenditures. Fostair® and Relvar®
now account for 24.5% of total expenditure on LABAs/ICS
(2017) in Scotland and growing rapidly (6.8% in 2015 and
13.2% in 2016). This reduction in expenditure of Seretide®
and Symbicort® with a corresponding increase in expenditure
of alternative LABA/ICS inhalers such as Fostair® and Relvar®
have also been significant (p < 0.001).
4. Discussion
The utilization patterns of the different inhaler types for
patients with asthma and COPD (Figure 1) are in line with
national and regional guidance (Table 1) with inhaled ICS used
initially in patients with asthma, with combination ICS/LABAs
used for maintenance and further treatments added when
required. In patients with COPD, LAMAs are increasingly
recommended alongside LABA/LAMA combinations as well
as triple therapy with increasing fears about using combina-
tion LABAs/ICSs unless patients also have asthmatic features
(Table 1). The effect of these guidelines can also be seen with
limited utilizing of mast cell stabilizers (Figure 1) in line with
their exclusion.
The growth in the utilization of inhalers in Scotland is also in
line with increasing prevalence rates especially for COPD [5]. The
higher utilization of Seretide® over Symbicort® (Figure 3) may be
due to the preference of clinicians as opposed to any appreciable
differences in clinical outcomes. This may have arisen because
GSK is a long-standing company in this area in the UK, initially
through Allen and Hanburys. However, further research is
needed before any definitive statements can be made.
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Inhaler expenditure increased from GB£48.64 million in
2001 to GB£85.91 million in 2010 and to GB £95.17 million in
2017 (Figure 2), enhanced by the prescribing of Seretide®,
Symbicort®, and Spiriva®. Traditionally, as mentioned, the
focus of managing patients with asthma and COPD in
Scotland has been on educating patients to improve their
inhaler technique and adherence rates [33,38]. In addition,
making sure optimal doses of ICS are given, which in recent
years has meant a reduction in the steroid burden (Table 1).
However, the high and growing expenditure on originator ICS/
LABAs up to 2010 resulted in Health Board initiatives to
increase the use of alternative inhalers (Table 1 – Figure 3).
Concurrent with this, there has been ongoing monitoring of
patients to ensure care is not compromised. In addition, reg-
ular monitoring of inhaler prices especially when originator
companies lower their prices to help retain or slow down their
decline in utilization. The increasing use of alternative inhalers,
coupled with initiatives to reduce the steroid burden and
associated costs, appear to have moderated the growth in
overall inhaler expenditure (Figures 2 and 4) for now at least.
The usage and expenditure patterns for respiratory inhalers
(Figures 1 and 2) did not follow the same patterns as seen with
other common classes of medicines prescribed in ambulatory
care in Scotland when medicines lose their patent such as
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antihypertensive medicines, PPIs, SSRIs and statins [42–44,53].
Consequently, we did not see appreciable reductions in inhaler
expenditures as the constituent medicines lost their patents
with the launch of newer inhalers replacing the older ones
(Appendix 1A) and, as mentioned, price reductions with
newer inhalers being more modest [42,43]. As a result, expen-
diture on inhalers increased by 195.7% between 2001 and 2017
with utilization only increasing by 137.1%. This increase in
expenditure reflects the promotion of ICS/LABA combination
therapies until recently for patients with COPD (Table 1), the
more modest price reductions of Fostair® and Relvar® compared
to Symbicort® and Seretide®, as well as the challenges of treat-
ing patients with respiratory diseases including concerns with
regularly switching patients between inhalers particularly if
there are color changes [80]. This was an issue with Relvar®
limiting initially its use in practice. Concerns with switching
patients to different inhalers whose condition is relatively con-
trolled have the potential for increasing exacerbations. The
extent though of this increased risk is under debate with
some authors suggesting that any risk is so high that any
switching of inhalers is unwarranted and could be costly
[38,52,81]; however, others have suggested there is no real
risk and patient care and clinical outcomes are of the same
standard when using alternative inhalers [82].
Overall, constant monitoring of patients coupled with
education on inhaler techniques as well as other initiatives
helps ensure patients in Scotland are treated as well as
possible within available resources. Such approaches are
facilitated by the fact that community pharmacists cannot
substitute branded medicines in the UK [42]. This situation is
being closely monitored though in view of the recognized
need to continue to offer high standards of care to patients
with asthma and COPD in Scotland but mindful of the
current high expenditure on inhalers. There are also con-
cerns that the expiry dates of the newer inhalers are being
reduced once opened, and this situation will also be closely
monitored. One potential approach is that all key stake-
holder groups become used to a more limited number of
inhalers so adherence and outcomes can be maximized.
However, the range has to be sufficient to cover patient
needs.
4.1. Limitations
We are aware it cannot be categorically assumed that all
inhalers in this study are being prescribed for the treatment
of asthma or COPD. However, it is believed that the prescrib-
ing of these inhalers for other indications is currently very
limited. There was also an inability to assess adherence to
the different inhalers including the newer combination inha-
lers, or their impact on patient outcomes, using the PCA data.
In addition, prescribing and dispensing data are not always
equal to each other. Despite these limitations, we believe our
findings are robust providing direction for the future.
5. Expert opinion
There has been considerable growth in the utilisation of com-
bination inhalers involving long acting b-agonists (LABAs) and
inhaled corticosteroids in Scotland in recent years to treat an
increasing number of patients with asthma and COPD in line
with current guidelines. Different patented inhalers have been
made available over the years to help address concerns with
compliance with inhalers with patients typically involved in
their selection. However, the increasing prevalence of respira-
tory diseases, coupled with patent protection for different
inhaler types, has resulted in inhalers becoming the second
highest category for drug expenditure in Scotland in recent
years. This has focused attention on newer lower cost combi-
nation inhalers. There were initially concerns that the newer
inhalers did not have the same dosage range as Seretide® and
Symbicort®, and it took time for all key stakeholder groups to
become comfortable with their use. This resulted in a slower
uptake initially to ensure patient care was not compromised.
This has started to change with more rapid growth rates in
recent years. It is likely the use of lower cost alternative
combination inhalers will continue to grow to help conserve
resources. This together with initiatives to reduce the steroid
burden in patients has resulted in expenditure on inhalers
stabilising in recent years. This is likely to continue with recent
guidelines advocating caution in the use of combination inha-
lers in patients with COPD counteracting any increased utilisa-
tion from any future growth in prevalence rates. Overall, the
inhaler market is very different to the oral market where there
have been substantial reductions in expenditure in classes
following the availability of low cost generics. This is likely to
remain with more modest price reductions envisaged for the
newer alternative combination inhalers versus the originators.
6. Conclusion
We believe this is the first comprehensive study in the UK and
across Europe to evaluate the influence of multiple interna-
tional, national and regional initiatives on the utilization and
expenditure patterns of different inhalers used for the man-
agement of asthma and COPD in recent years.
Overall, the utilization and expenditure patterns for inhalers
used for the treatment of asthma and COPD in Scotland have
not experienced the same trends as other high volume classes
in ambulatory care in terms of decreasing expenditure despite
increasing utilization once standard medicines in the class lose
their patent. This is due to a number of factors including the
need to have a range of inhalers to choose from, the patent
situation associated with new devices and new formulations,
concerns with switching, and more modest price reductions
with the newer alternative combination inhalers compared to
their originators.
For any health service with finite resources, cost is a key
consideration as seen recently regarding Scotland’s Health
Board advice on Fostair® and Relvar®. However, improved patient
care and safety is paramount for patients with asthma and COPD
as seen by the various international, national and regional initia-
tives and guidelines which have appreciably influenced prescrib-
ing patterns in Scotland, most notably resulting in the increasing
use of LABA/ICS inhalers (until recently) and reduced prescribing
of single agent ICS and LABA inhalers. However, further research
is needed to fully assess the cost-effectiveness of the different
approaches in Scotland including educational and other
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initiatives to enhance patient adherence and improve future care
efficiently. Ideally, all key stakeholder groups should work
together to rationalize the inhaler choices available and improve
familiarity to help conserve costs within a constrained resource
environment. These are projects for the future.
Key issues
● There is increasing prevalence of asthma and COPD across
countries, with both priority areas in Scotland
● There has been the continual launch of new patented inhalers
to help address concerns with adherence to inhalers. This
coupled with increased prevalence rates has meant a two-
fold increase in inhaler expenditure in Scotland between 2001
and 2017
● As a result, NHS Scotland spends over GB£125 million
per year on respiratory medicines, with expenditure on
LABA/ICS and LAMA inhalers becoming the highest of any
medicine type in Scotland
● However, concerns with the availability of the full dose range
of alternative combination inhalers to Seretide® over
Symbicort®, coupled with the need to be cautious initially
as health-care professionals and patients became more famil-
iar with alternative inhalers and their more modest price
reductions have resulted in total expenditure in inhalers
plateauing in recent years compared with the appreciable
reductions in expenditure on oral medicines once generics
become available. Recent initiatives to reduce the steroid
burden have also impacted on expenditures
● There is ongoing monitoring of patients to ensure care is
not compromised with the increasing use of alternative
combination inhalers, and this will continue
● The utilization of combination ICS/LABAs in COPD will be
affected by recent concerns with their safety
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Appendix
Table 1A. Summary of different inhaler drug classes (Source ISD Scotland – [55]).
Drug Class Active Ingredient Originator Number of strengths and formulations (2001 vs. 2017)
SABA Salbutamol Ventolin® 19–15
Terbutaline Sulfate Bricanyl® 6–2
Fenoterol Hydrobromide Duovent® 6–0
Orciprenaline Sulfate Alupent® 4–0
Reproterol Hydrochloride Bronchodil® 2–0
SAMA Ipratropium Bromide Atrovent® 6–2
Oxitropium Bromide Oxivent® 4–0
LAMA Tiotropium Spiriva Respimat® 0–2
Aclidinium Bromide Eklira Genuair® 0–2
Umeclidinium Bromide Incruse Ellipta® 0–2
Mast Cell Stabilizers Nedocromil Sodium Tilade® 4–2
Sodium Cromoglicate Intal® 8–2
ICS Budesonide Pulmicort® 10–14
Beclometasone Dipropionate Becotide® 42–19
Ciclesonide Alvesco® 6
Fluticasone Propionate Flixotide® 22–14
Mometasone Furoate Asmanex® 0–8
SABA/SAMA Salbutamol/Ipratropium Combivent® 1–0
LAMA/LABA Umeclidinium Bromide/Vilanterol Anoro® 0–0
Tiotropium/Olodaterol Spiolto Respimat® 0–1
ICS/LABA Salmeterol/Fluticasone Propionate Seretide® 0–11
Budesonide/Formoterol Fumarate Symbicort® 0–6
Fluticasone Furoate/Vilanterol Relvar Ellipta® 0–2
Fluticasone Propionate/Formoterol Fumarate Flutiform® 0–3
Beclometasone Dipropionate/Formoterol Fumarate Fostair® 0–4
ICS/SABA Beclometasone Dipropionate/Salbutamol Ventide® 1–0
NB: There have been changes in the availability of different inhaler types during the course of the study as well as CFC and CFC-inhaler types. Some formulations
were also never licensed in the UK but may have had limited use.
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